Innovita Biological Technology Co (SHSE:688253) Cash-to-Debt : 600.28 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Innovita Biological Technology Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innovita Biological Technology Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 600.28.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Innovita Biological Technology Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Innovita Biological Technology Co's Cash-to-Debt or its related term are showing as below:

SHSE:688253' s Cash-to-Debt Range Over the Past 10 Years
Min: 22.12 Med: 274.72 Max: No Debt
Current: 600.28

During the past 6 years, Innovita Biological Technology Co's highest Cash to Debt Ratio was No Debt. The lowest was 22.12. And the median was 274.72.

SHSE:688253's Cash-to-Debt is ranked better than
86.28% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs SHSE:688253: 600.28

Innovita Biological Technology Co Cash-to-Debt Historical Data

The historical data trend for Innovita Biological Technology Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Innovita Biological Technology Co Cash-to-Debt Chart

Innovita Biological Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

57.74

404.70

65.02

566.63

Innovita Biological Technology Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												275.27	334.14	427.63	566.63	600.28

Competitive Comparison of Innovita Biological Technology Co's Cash-to-Debt

For the Biotechnology subindustry, Innovita Biological Technology Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovita Biological Technology Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innovita Biological Technology Co's Cash-to-Debt falls into.

Innovita Biological Technology Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innovita Biological Technology Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1697.046	/	(1.958	+	1.037)
	=	566.63

Innovita Biological Technology Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1818.858	/	(1.618	+	1.412)
	=	600.28

Innovita Biological Technology Co (SHSE:688253) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innovita Biological Technology Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Innovita Biological Technology Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovita Biological Technology Co (SHSE:688253) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovita Biological Technology Co Ltd (SHSE:688253) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Courtyard, Haiying Road, 1st Floor, 2nd Floor, Building 6, Fengtai District, Beijing, CHN, 100071

Website

https://www.innovita.com.cn

Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production and sales of POCT in vitro diagnostic products.

Innovita Biological Technology Co (SHSE:688253) Headlines

No Headlines